Highlights of weekly biotech stock moves

Alimera Sciences Inc. (NASDAQ:ALIM) fell $0.39 (14%) to $2.41 on Wednesday after the U.K.'s NICE issued draft guidance recommending against the use of Iluvien fluocinolone acetonide intravitreal implant to treat chronic diabetic macular edema (DME) (see B11).

Alimera has rights from pSivida Corp. (NASDAQ:PSDV; ASX:PVA), which dropped $0.39 (19%) to $1.70 on Wednesday. In Australia, the stock fell A$0.35 (17%) to A$1.75...